23.80

1.00% -0.24

After Hours: 23.80

Janux Therapeutics Inc (JANX)

Overview News Price History Option Chain Financials Discussions Forecast

Janux Therapeutics Inc stock is traded at $23.80, with a volume of 1.06M. It is down -1.00% in the last 24 hours and down -26.88% over the past month. Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Previous Close:

$24.04

Open:

$23.7

24h Volume:

1.06M

Relative Volume:

1.07

Market Cap:

$1.41B

Revenue:

$13.05M

Net Income/Loss:

$-60.54M

P/E Ratio:

-20.52

EPS:

-1.16

Net Cash Flow:

$-37.82M

1W Performance:

-5.63%

1M Performance:

-26.88%

6M Performance:

-47.36%

1Y Performance:

-52.79%

1-Day Range:

$23.05

$24.27

1-Week Range:

$23.05

$25.75

52-Week Range:

$22.48

$71.71

Janux Therapeutics Inc Stock (JANX) Company Profile

Name

Janux Therapeutics Inc

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

(858) 751-4493

Address

10955 VISTA SORRENTO PARKWAY, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-08-06

Latest SEC Filings

JANX's Discussions on Twitter

Compare JANX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JANX Janux Therapeutics Inc	23.80	1.49B	13.05M	-60.54M	-37.82M	-1.16
ONC Beone Medicines Ltd Adr	245.58	26.10B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.96B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	42.96M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.39B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	63.52B	14.09B	4.50B	2.96B	39.28

Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-24	Reiterated	BTIG Research	Buy
Dec-03-24	Reiterated	H.C. Wainwright	Buy
Nov-22-24	Initiated	Leerink Partners	Outperform
Oct-24-24	Initiated	UBS	Buy
Sep-06-24	Initiated	Stifel	Buy
May-30-24	Initiated	Scotiabank	Sector Perform
Mar-21-24	Initiated	BTIG Research	Buy
Mar-20-24	Initiated	Cantor Fitzgerald	Overweight
Apr-06-23	Initiated	Wedbush	Outperform
Nov-14-22	Initiated	William Blair	Outperform

View All

Janux Therapeutics Inc Stock (JANX) Latest News

May 30, 2025

SA Asks: Which oncology companies are attractive M&A targets? - Seeking Alpha

May 30, 2025

Nuveen Asset Management LLC Sells 39,145 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

May 30, 2025

May 28, 2025

Millennium Management LLC Invests $6.22 Million in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

May 28, 2025

May 27, 2025

BNP Paribas Financial Markets Purchases New Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

May 27, 2025

May 23, 2025

When the Price of (JANX) Talks, People Listen - news.stocktradersdaily.com

May 23, 2025

May 20, 2025

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of “Buy” by Analysts - Defense World

May 20, 2025

How Vir CEO Marianne De Backer Is Rebuilding Commercial Momentum - insights.citeline.com

May 20, 2025

May 15, 2025

Janux appoints Janeen Doyle chief corporate, business development officer - TipRanks

May 15, 2025

Janux Therapeutics (JANX) Welcomes New Chief Corporate and Busin - GuruFocus

May 15, 2025

Janux Therapeutics (JANX) Welcomes New Chief Corporate and Business Development Officer | JANX Stock News - GuruFocus

May 15, 2025

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer - Bluefield Daily Telegraph

May 15, 2025

Northern Trust Corp Buys 42,302 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

May 15, 2025

Leerink cuts Janux Therapeutics price target to $89, keeps Outperform By Investing.com - Investing.com India

May 12, 2025

May 10, 2025